I guess we’ll just take their word on it:
How have they already conducted a study about the Omicron variant? It’s like 10 days old.
They’ve already completed a rigorous study accounting for long-term effects, and had it peer-reviewed?
By the way, and I’m sure this has nothing to do with anything here, just figured I’d throw it out there:
With its coronavirus vaccine on track this year to generate the biggest single-year sales ever for a medical product, Pfizer on Tuesday disclosed revenue projections indicating that the shot will likely beat that record or come close in 2022.
The company said while reporting its third quarter earnings that it expects its vaccine to bring in $36 billion in revenue this year. Pfizer said it has already reached supply deals worth $29 billion in revenue for its vaccine next year, covering 1.7 billion shots it has already committed to countries around the world. Billions more in sales are likely to come as the company reaches more deals to sell to governments the four billion shots it expects to produce next year.
By my tally that’s at least $65 billion now, with plenty more to be added on top of that given that if we go by the ratio of 1.7 billion shots = $29 billion, that comes out to about $17 a shot, meaning an additional 4 billion shots would bring in an additional $68 billion on top of the $65 billion they are already currently projecting.
Maybe my math is off, so correct me if I’m wrong here. But it does appear as if Pfizer will, between this year and next, have pulled in north of $130 billion from this vaccine.
Meanwhile, Covid is such a serious, urgent and deadly pandemic that Pfizer is only selling the vaccine to rich countries and complains that poor countries can’t afford its vaccine:
The company’s chief executive, Dr. Albert Bourla, told analysts on Tuesday that most of the company’s negotiations are with high- and upper-middle-income countries. He said he was concerned that poorer countries and their proxies were not lining up to place orders. “I don’t want to reach a level that again the low- and middle-income countries will be behind in their deliveries because they didn’t place their orders,” he said.
Pfizer says it is selling shots for poorer countries at discounted prices, but many of the world’s poorest countries cannot afford to buy doses directly. They have depended on donations from the United States and other wealthy countries, and on supply from Covax, the United Nations program to vaccinate the globe.
I’m laughing at the idea that Pfizer wants credit for selling its shots to poorer countries at “discounted prices,” and yet most of those poor countries still can’t afford the shots.
What kind of discount is that?
Pfizer should get no credit for making something that is unaffordable only slightly less unaffordable.
It just makes you think, though. If Covid was really as urgent and deadly as they say it is, then how would Pfizer be allowed to profit off of this vaccine?
If it was truly urgent, it would be free. It would be non-profit. The goal would be widespread distribution as quickly as possible, not negotiations over prices.
It’s so urgent and important, we can only give the vaccine to countries that can afford it:
There remain stark differences in vaccine access: Worldwide, about 75 percent of all shots that have gone into arms have been administered in high- and upper-middle-income countries, according to the Our World in Data project at the University of Oxford. Only 0.6 percent of doses have been administered in low-income countries.
Wow, it’s almost as if this is more about making money than saving lives.
The enormous sales figures will translate into billions in profits for Pfizer. The company, which must split its vaccine revenue with development partner BioNTech, said that it expects its profit margins on the vaccine will be in the high 20 percent range next year, the same margin it projected this year.
Okay, so if total revenues will be in the $133 billion range for the vaccine and profit margins in the “high 20% range” (we’ll call it 27%), that comes out to a profit of about $36 billion overall. Profit.
But if you think they’re satisfied with that, guess again:
The doses that will be delivered next year include booster shots, mostly for wealthier countries, and primary immunizations, with an emphasis on second doses, for poorer countries.
Think about the math behind booster shots: if you’re already making billions upon billions of dollars off of a 2-shot vaccine, a booster shot increases your revenues, in theory, by 50%. Going from 2 to 3 shots is a 50% increase in shots, right?
But that’s not all. They’re trying to expand their market:
A small chunk of the doses will be given to children. The company won authorization last week for its vaccine to be given in the United States to children between the ages of 5 and 11. An advisory panel to the Centers for Disease Control and Prevention voted unanimously on Tuesday to recommend pediatric doses for that age group, and if the director signs off, children could begin receiving it this week.
Not that the children need the shots or anything. But none of this is about health. It’s about the vaccine.
Oh, and Pfizer isn’t done, either.
Pfizer expects to have initial data from its studies evaluating its vaccine in children between the ages of 2 and 4 by the end of December and in children between the ages of six months and 1 by the end of March, the company’s research chief, Dr. Mikael Dolsten, told analysts on Tuesday.
They want to vaccinate SIX MONTH OLD BABIES!
I’m sure they won’t even be satisfied with that, either.
I’m sure by the middle of 2022 they’ll be pushing for mandatory vaccination shots to be administered at birth. The second a baby pops out of the womb, boom, jabbed with Pfizer vax.
And get a mask on that baby for fuck’s sake!
No, I don’t care if he’s still attached by his umbilical cord, he needs to be social distancing, damnit!
What, is it really that crazy to imagine?